Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for HIV patients with rare brain disease?

NCT ID NCT00120367

Disease control Sponsor: French National Agency for Research on AIDS and Viral Hepatitis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a powerful HIV drug called FUZEON® to standard antiretroviral therapy could help people with HIV who also have a rare brain infection called PML. PML is caused by a virus that attacks the brain when the immune system is weak. The goal was to see if the stronger drug combination could stop the infection from getting worse. The study included 30 adults in France and followed them for one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

Start date

Apr 2005

Finished

Dec 2007

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age and older * Have confirmed laboratory diagnosis of HIV infection * Presenting with a clinical history of active PML evolving (or continuing to deteriorate) for less than 90 days * Diagnosis of PML documented for less than 30 days at the inclusion by cerebral imaging (MRI) AND the absence of another demonstrated etiology AND the detection of JCV DNA in the CSF by qualitative PCR. * Signed written inform consent Exclusion Criteria: * Concomitant opportunistic infection of the central nervous system * Pregnancy, breast-feeding * Co-infection by the HIV2 * History of immunotherapy including interleukin-2 and alpha-interferon * History of treatment by FUZEON® or by cidofovir * Contra-indication to receive FUZEON

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease progressive multifocal leukoencephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infections Leukoencephalopathy, progressive multifocal

Contacts and locations

Locations

  • Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre

    Le Kremlin-Bicêtre, 94270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.